IP Library › Granted Patent US 12,383,553
Granted Patent B2
US 12,383,553 · App. 18/091,145 · Granted Aug 12, 2025

Method for detecting or treating triple negative breast cancer

Inventors: Debra Auguste (Briarcliff Manor, NY); Marsha A. Moses (Brookline, MA); Peng Guo (Natick, MA)
Assignee: Children's Medical Center Corporation
A61K31/4965A61K9/14A61K31/191A61K31/429A61K31/4365A61K47/555C12Q1/6886G01N33/57415A61K2121/00C12Q2600/158G01N2333/70525
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,383,553
App. No.
18/091,145
Granted
Aug 12, 2025
Kind
B2
Abstract

A method of detecting triple negative breast cancer (TNBC) is provided. Overexpression of ICAM-1 is linked to an increased risk of TNBC. A composition of matter is also provided that binds an anti-ICAM˜1 antibody to a nanoparticle. The composition may be used as an imaging agent and/or a therapeutic targeting agent. A therapeutically active molecule may be bound to the composition to provide targeted therapy.

Claims (5)

1. A method of treating triple negative breast cancer (TNBC) in a patient, the method comprising administering enlimomab to the patient, wherein administering the enlimomab reduces TNBC cell migration in the patient.

2. The method of claim 1 , wherein the patient is a human patient.

3. The method of claim 1 , wherein the TNBC of the patient comprises a mutation in the BRCA1 gene.

4. The method of claim 1 , wherein ICAM-1 is expressed by TNBC cells of the patient.

5. The method of claim 1 , wherein ICAM-1 is expressed on the surface of TNBC cells of the patient.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2024
From: MOSES, MARSHA A.
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 068647/0104 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2024
From: AUGUSTE, DEBRA; GUO, PENG
To: RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK
Reel/Frame 068647/0107 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2024
From: RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 068647/0112 →
Continuity (3)
Continuation 15127240
Provisional Application 61970943 · Mar 27, 2014
Related Publication 20230248721A1 · Aug 10, 2023
References Cited (128)
US 5284931A · Springer et al. · 1994 [cited by applicant]
US 5288854A · Diamond et al. · 1994 [cited by applicant]
US 5475091A · Springer · 1995 [cited by examiner]
US 5626870A · Minshipouri et al. · 1997 [cited by applicant]
US 6203793B1 · Lipsky · 2001 [cited by examiner]
US 6316024B1 · Allen et al. · 2001 [cited by applicant]
US 6569451B1 · Bednarski et al. · 2003 [cited by applicant]
US 9388249B2 · Sugioka et al. · 2016 [cited by applicant]
US 9737492B2 · Mao et al. · 2017 [cited by applicant]
US 10092188B2 · Jaffer et al. · 2018 [cited by applicant]
US 10421758B2 · Chiosis et al. · 2019 [cited by applicant]
US RE48787E · Adair et al. · 2021 [cited by applicant]
US 11260132B2 · Moses · 2022 [cited by examiner]
US 20020071843A1 · Bednarski et al. · 2002 [cited by applicant]
US 20040013720A1 · Ellens et al. · 2004 [cited by applicant]
US 20070111331A1 · Hong et al. · 2007 [cited by applicant]
US 20070280948A1 · Williams et al. · 2007 [cited by applicant]
US 20080187595A1 · Jordan et al. · 2008 [cited by applicant]
US 20090186078A1 · Kliche et al. · 2009 [cited by applicant]
US 20100008978A1 · Drummond et al. · 2010 [cited by applicant]
US 20100209490A1 · Morita et al. · 2010 [cited by applicant]
US 20100285002A1 · Peer et al. · 2010 [cited by applicant]
US 20110244048A1 · Amiji et al. · 2011 [cited by applicant]
US 20130034548A1 · Moyo et al. · 2013 [cited by applicant]
US 20130064763A1 · Abulrob et al. · 2013 [cited by applicant]
US 20140127187A1 · Niitsu et al. · 2014 [cited by applicant]
US 20140127287A1 · Xiong et al. · 2014 [cited by applicant]
US 20140314666A1 · Muro Galindo et al. · 2014 [cited by applicant]
US 20150064265A1 · Fahmy et al. · 2015 [cited by applicant]
US 20170173005A1 · Auguste et al. · 2017 [cited by applicant]
US 20200085972A1 · Moses et al. · 2020 [cited by applicant]
US 20210113466A1 · Moses et al. · 2021 [cited by applicant]
US 20220280653A1 · Moses et al. · 2022 [cited by applicant]
US 20240148888A1 · Guo et al. · 2024 [cited by applicant]
EP 2468775A1 · 2012 [cited by applicant]
WO WO199116928A1 · 1991 [cited by applicant]
WO WO1998016201A1 · 1998 [cited by applicant]
WO WO1998016202A1 · 1998 [cited by applicant]
WO WO0236073A2 · 2002 [cited by applicant]
WO WO2006116107A2 · 2006 [cited by applicant]
WO WO2007127219A2 · 2007 [cited by applicant]
WO WO2007127221A2 · 2007 [cited by applicant]
WO WO2007127272A2 · 2007 [cited by applicant]
WO WO2009026328A2 · 2009 [cited by applicant]
WO WO2012007516A1 · 2012 [cited by applicant]
WO WO2012106559A1 · 2012 [cited by applicant]
WO WO2012155048A1 · 2012 [cited by applicant]
WO WO2014046630A1 · 2014 [cited by applicant]
WO WO2015066535A1 · 2015 [cited by applicant]
WO WO2015089419A2 · 2015 [cited by applicant]
WO WO2015148971A2 · 2015 [cited by applicant]
WO WO2015191693A2 · 2015 [cited by applicant]
WO WO2016064882A1 · 2016 [cited by applicant]
WO WO2017223135A1 · 2017 [cited by applicant]
WO WO2022182743A1 · 2022 [cited by applicant]
Cybulsky MI, Fries JW, Williams AJ, et al. Alternative splicing of human VCAM-1 in activated vascular endothelium. Am J Pathol 1991; 138: 815-20. (Year: 1991). [cited by examiner]
Rosette et al. Role of ICAM1 in invasion of human breast cancer cells. Carcinogenesis, 25(5):943-950, 2005. (Year: 2005). [cited by examiner]
Chavez et al. Triple Negative Breast Cancer Cell Lines: One Tool in the Search for Better Treatment of Triple Negative Breast Cancer. Breast Dis. 2010 ; 32(1-2): 35-48. (Year: 2010). [cited by examiner]
Schlesinger and Bendas. Vascular cell adhesion molecule-1 (VCAM-1)-An increasing insight into its role in tumorigenicity and metastasis. IJC, 136(11):2504-2514, 2015 (Year: 2015). [cited by examiner]
Nizamutdinova et al. Tanshinone I suppresses growth and invasion of human breast cancer cells, MDA-MB-231, through regulation of adhesion molecules. Carcinogenesis vol. 29 No. 10 pp. 1885-1892, 2008. (Year: 2008). [cited by examiner]
[No Author Listed]Enlimomab Acute Stroke Trial Investigators. Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology. Oct. 23, 2001;57(8):1428-34. [cited by applicant]
Buitrago et al., Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma. Ann Surg Oncol. Mar. 2012;19(3):973-80. [cited by applicant]
Cahall et al., A Quantitative Perspective on Surface Marker Selection for the Isolation of Functional Tumor Cells. Breast Cancer (Auckl). Jul. 27, 2015;9(Suppl 1):1-11. [cited by applicant]
Carter et al., Antibody-drug conjugates for cancer therapy. Cancer J. May-Jun. 2008;14(3):154-69. [cited by applicant]
Chen et al., Mechanism of apoptosis induced by urosolic acid in gastric carcinoma BGC-823 cells. Wuhan Daxue Xuebao, Yixueban. 2006;27(3):299-302. English Abstract Only. [cited by applicant]
Chen et al., Targeted Delivery of CRISPR/Cas9-Mediated Cancer Gene Therapy via Liposome-Templated Hydrogel Nanoparticles. Adv Funct Mater. Dec. 8, 2017; 27(46): 1-18. [cited by applicant]
Chen, Small-molecule delivery by nanoparticles for anticancer therapy. Trends Mol Med. Dec. 2010;16(12):594-602. [cited by applicant]
Chittasupho et al., ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells. Eur J Pharm Sci. May 12, 2009;37(2):141-50. [cited by applicant]
Claesson-Welsh et al., Permeability of the Endothelial Barrier: Identifying and Reconciling Controversies. Trends Mol Med. Apr. 2021;27(4):314-331. [cited by applicant]
Clauss et al., A permissive role for tumor necrosis factor in vascular endothelial growth factor-induced vascular permeability. Blood. Mar. 1, 2001;97(5):1321-9. [cited by applicant]
Crown et al., Emerging targeted therapies in triple-negative breast cancer. Ann Oncol. Aug. 2012;23 Suppl 6:vi56-65. [cited by applicant]
Dan et al., Binding, transcytosis and biodistribution of anti-PECAM-1 iron oxide nanoparticles for brain-targeted delivery. PLoS One. Nov. 20, 2013;8(11):e81051. [cited by applicant]
Ding et al., A non-cationic nucleic acid nanogel for the delivery of the CRISPR/Cas9 gene editing tool. Nanoscale. 2019;11:17211-17215. [cited by applicant]
Ducry et al., Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem. Jan. 2010;21(1):5-13. [cited by applicant]
Grijalvo et al., Biodegradable liposome-encapsulated hydrogels for biomedical applications: a marriage of convenience. Biomater Sci. Apr. 2016;4(4):555-74. [cited by applicant]
Gunawan et al., Complementary targeting of liposomes to IL-1α and TNF-α activated endothelial cells via the transient expression of VCAM1 and E-selectin. Biomaterials. Dec. 2011;32(36):9848-53. [cited by applicant]
Guo et al., Abstract 4410: An ICAM-1-targeted, Lcn2 siRNA-encapsulating liposome as a potent anti-angiogenic agent for triple-negative breast cancer. In: Proceedings of the 106th Annual Meeting of the American Associati… [cited by applicant]
Guo et al., ICAM-1 as a molecular target for triple negative breast cancer. Proc Natl Acad Sci U S A. Oct. 14, 2014;111(41):14710-5. [cited by applicant]
Guo et al., ICAM-1-Targeted, Lcn2 siRNA-Encapsulating Liposomes are Potent Anti-angiogenic Agents for Triple Negative Breast Cancer. Theranostics. Jan. 1, 2016;6(1):1-13. [cited by applicant]
Guo et al., Inhibiting metastatic breast cancer cell migration via the synergy of targeted, pH-triggered siRNA delivery and chemokine axis blockade. Mol Pharm. Mar. 3, 2014;11(3):755-65. [cited by applicant]
Guo et al., Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel. Proc Natl Acad Sci U S A. Sep. 10, 2019;116(37):18295-18303. doi: 10.1073/pnas.1904697116. Epub Aug… [cited by applicant]
Hendriks et al., Impact of tumor HER2/ERBB2 expression level on HER2-targeted liposomal doxorubicin-mediated drug delivery: multiple low-affinity interactions lead to a threshold effect. Mol Cancer Ther. Sep. 2013;12(9)… [cited by applicant]
Huang et al., Casein-coated iron oxide nanoparticles for high MRI contrast enhancement and efficient cell targeting. ACS Appl Mater Interfaces. Apr. 2013;5(11):4632-4639. [cited by applicant]
Jung et al., Expression of intercellular adhesion molecule-1 and e-selectin in gastric cancer and their clinical significance. J Gastric Cancer. Sep. 2012;12(3):140-8. [cited by applicant]
Kelly et al., Human colon cancer cells express ICAM-1 in vivo and support LFA-1-dependent lymphocyte adhesion in vitro. Am J Physiol. Dec. 1992;263(6 Pt 1):G864-70. [cited by applicant]
Liu et al., Self-assembled nanoparticles based on a carboxymethylcellulose-ursolic acid conjugate for anticancer combination therapy. RSC Advances. 2017;7:36256. [cited by applicant]
Manikwar et al., Utilization of I-domain of LFA-1 to Target Drug and Marker Molecules to Leukocytes. Theranostics. 2011;1:277-89. doi: 10.7150/thno/v01p0277. Epub May 10, 2011. [cited by applicant]
Maruo et al., ICAM-1 expression and the soluble ICAM-1 level for evaluating the metastatic potential of gastric cancer. Int J Cancer. 2002;100:486-490. [cited by applicant]
Mastrobattista et al., Cellular uptake of liposomes targeted to intercellular adhesion molecule-1 (ICAM-1) on bronchial epithelial cells. Biochim Biophys Acta. Jul. 15, 1999;1419(2):353-63. [cited by applicant]
Morral-Ruiz et al., Multifunctional polyurethane-urea nanoparticles to target and arrest inflamed vascular environment: a potential tool for cancer therapy and diagnosis. J Control Release. 2013;171(2):163-171. [cited by applicant]
Muro et al., Control of intracellular trafficking of ICAM-1-targeted nanocarriers by endothelial Na+/H+ exchanger proteins. Am J Physiol Lung Cell Mol Physiol. May 2006;290(5):L809-17. doi: 10.1152/ajplung.00311.2005. E… [cited by applicant]
Muro et al., Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis. Mol Ther. Jan. 2006;13(1):135-41. doi: 10.1016/j.ymthe.2005.07.687. Epub Sep. 8, 2005. [cited by applicant]
Muro et al., Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress. Am J Physiol Cell Physiol. 2003;285:C1339-C1347. [cited by applicant]
Murphy et al., Targeted nanogels: a versatile platform for drug delivery to tumors. Mol Cancer Ther. Jun. 2011;10(6):972-82. doi: 10.1158/1535-7163.MCT-10-0729. Epub Apr. 25, 2011. [cited by applicant]
Oh et al., Endocytosis and exocytosis of nanoparticles in mammalian cells. Int J Nanomedicine. May 6, 2014;9 Suppl 1(Suppl 1):51-63. [cited by applicant]
Pannier et al., Surface- and hydrogel-mediated delivery of nucleic acid nanoparticles. Methods Mol Biol. 2013;948:149-69. [cited by applicant]
Papademetriou et al., Comparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptor. J Inherit Metab Di… [cited by applicant]
Park et al., Characterization of radioligand binding to a transmembrane receptor reconstituted into Lipobeads. FEBS Lett. Jun. 4, 2004;567(2-3):344-8. doi: 10.1016/j.febslet.2004.03.124. [cited by applicant]
Rosette et al., Role of ICAM1 in invasion of human breast cancer cells. Carcinogenesis. Mar. 17, 2005;26(5):943-950. [cited by applicant]
Senter, Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol. Jun. 2009;13(3):235-44. [cited by applicant]
Shimoyama et al., Overexpression of intercellular adhesion molecule-1 (ICAM-1) in pancreatic adenocarcinoma in comparison with normal pancreas. Pancreas. Mar. 1997;14(2):181-6. [cited by applicant]
Song et al., Development and characterisation of ursolic acid nanocrystals without stabiliser having improved dissolution rate and in vitro anticancer activity. AAPS PharmSciTech. Feb. 2014;15(1):11-19. [cited by applicant]
Sughrue et al., Anti-adhesion molecule strategies as potential neuroprotective agents in cerebral ischemia: a critical review of the literature. Inflamm Res. Oct. 2004;53(10):497-508. [cited by applicant]
Taniguchi et al., Effects of the anti-ICAM-1 monoclonal antibody on dextran sodium sulphate-induced colitis in rats. J Gastroenterol Hepatol. Sep. 1998;13(9):945-9. [cited by applicant]
Usami et al., Intercellular adhesion molecule-1 (ICAM-1) expression correlates with oral cancer progression and induces macrophage/cancer cell adhesion. Int J Cancer. Aug. 1, 2013;133(3):568-78. [cited by applicant]
Villanueva et al., Microbubbles targeted to intercellular adhesion molecule-1 bind to activated coronary artery endothelial cells. Circulation. Jul. 7, 1998;98(1):1-5. [cited by applicant]
Wang et al., In Vivo Delivery Systems for Therapeutic Genome Editing. Int J Mol Sci. Apr. 27, 2016;17(5):626. doi: 10.3390/ijms17050626. [cited by applicant]
Xavier et al., Ursolic acid induces cell death and modulates autophagy through JNK pathway in apoptosis-resistant colorectal cancer cells. J Nutr Biochem. Apr. 2013;24(4):706-12. [cited by applicant]
Xu et al., Antibody conjugated magnetic iron oxide nanoparticles for cancer cell separation in fresh whole blood. Biomaterials. Dec. 2011;32(36):9758-9765. [cited by applicant]
Yu et al., Improved delivery of Cas9 protein/gRNA complexes using lipofectamine CRISPRMAX. Biotechnol Lett. Jun. 2016;38(6):919-29. [cited by applicant]
Zhang et al., Anti-ICAM-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in the rat. Neurology. Sep. 1994;44(9):1747-51. [cited by applicant]
Zhang et al., Delivery of ursolic acid (UA) in polymeric nanoparticles effectively promotes the apoptosis of gastric cancer cells through enhanced inhibition of cyclooxygenase 2 (COX-2). Int J Pharm. 2013;441:261-268. [cited by applicant]
Zhang et al., PLGA nanoparticle—peptide conjugate effectively targets intercellular cell-adhesion molecule-1. Bioconjug Chem. Jan. 2008;19(1):145-52. [cited by applicant]
[No Author Listed], Definition of “oligonucleotide” from biologyonline.com. Accessed as available Feb. 20, 2024 from < https://web.biology.com/dictionary/oligonucleotide>. [cited by applicant]
[No Author Listed], Definition of “polynucleotide” from biologyonline.com. Accessed as available Feb. 2, 20240 from <https://web.biology.com/dictionary/polynucleotide>. [cited by applicant]
Bhowmick et al., Effect of flow on endothelial endocytosis of nanocarriers targeted to ICAM-1. J Control Release. Feb. 10, 2012;157(3):485-92. doi: 10.1016/j.jconrel.2011.09.067. Epub Sep. 16, 2011. Author Manuscript, 1… [cited by applicant]
Edwards et al., The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS. J Mol Biol. Nov. 14, 2003;334(1):103-18. doi: 10.1016/j.jmb.200… [cited by applicant]
Goel et al., Plasticity within the antigen-combining site may manifest as molecular mimicry in the humoral immune response. J Immunol. Dec. 15, 2004;173(12):7358-67. doi: 10.4049/jimmunol.173.12.7358. [cited by applicant]
Kanyavuz et al., Breaking the law: unconventional strategies for antibody diversification. Nat Rev Immunol. Jun. 2019;19(6):355-368. doi: 10.1038/s41577-019-0126-7. [cited by applicant]
Lloyd et al., Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens. Protein Eng Des Sel. Mar. 2009;22(3):159-68. [cited by applicant]
Machado et al., Encapsulation of DNA in macroscopic and nanosized calcium alginate gel particles. Langmuir. Dec. 23, 2013;29(51):15926-35. doi: 10.1021/la4032927. Epub Dec. 11, 2013. [cited by applicant]
Murciano et al., ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface. Blood. May 15, 2003;101(10):3977-84. doi: 10.1182/blood-2002-09-2853. Epub Jan. 16, 2003. [cited by applicant]
Nograles et al., Formation and characterization of pDNA-loaded alginate microspheres for oral administration in mice. J Biosci Bioeng. Feb. 2012;113(2):133-40. doi: 10.1016/j.jbiosc.2011.10.003. Epub Nov. 16, 2011. [cited by applicant]
Elstrodt et al., BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res. Jan. 1, 2006;66(1):41-5. doi: 10.1158/0008-5472.CAN-05-2853. [cited by applicant]
Pisani et al., Neutral Liposomes and DNA Transfection. Excerpt from Non-Viral Gene Therapy, Chapter 14. Ed. Xubo Yuan. InTech. Nov. 2011:319-48. [cited by applicant]
Rae et al., MDA-MB-435 cells are derived from M14 melanoma cells—a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat. Jul. 2007;104(1):13-9. doi: 10.1007/s10549-006-9392-8. Epub Sep. 27, … [cited by applicant]
Xiong et al., Cationic liposomes as gene delivery system: transfection efficiency and new application. Pharmazie. Mar. 2011;66(3):158-64. [cited by applicant]
Brooks et al., The antitumor activity of an anti-CD54 antibody in SCID mice xenografted with human breast, prostate, non-small cell lung, and pancreatic tumor cell lines. Int J Cancer. Nov. 15, 2008;123(10):2438-45. doi… [cited by applicant]